Publication | Open Access

Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period

Alström SyndromePharmacologyClinical TrialsPharmacotherapyNeurologyMedicineBardet-biedl SyndromeOpen-label Period